To further confirm the prognosis of these findings, we performed co‐staining for pan‐cytokeratin, ASCL1, and KRT6A on clinical tumour samples from treatment‐naïve KRASG12C‐mutant LUAD, confirming the presence of two distinct subpopulations within individual tumours (Figure 2F). Here, KRT6A is linked to neoplasm.